Sisram Medical Ltd Announces Phase IIb Clinical Result on Submental Fat Reduction of JS-001
the adverse effects were local (mainly affecting the area of injection) and transient. Pre-clinical and clinical studies of JS-001 both demonstrate that JS-001 can induce adipocyte decay and reduce thickness of fat layer, and therefore it can be used for body contouring. A multi-regional phase III clinical trials (including mainland China) of JS-001 will be initiated in late 2022 to further verify its safety and efficacy.